Cargando…

Changes in cytokine responses to TB antigens ESAT-6, CFP-10 and TB 7.7 and inflammatory markers in peripheral blood during therapy

Multiple cytokines and inflammatory markers control TB infection. We aimed to investigate the changes in multiple cytokines and inflammatory markers in active TB patients following anti-TB drug therapy. Twenty-nine patients with active TB were recruited prospectively between December 2010 and July 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Leem, Ah Young, Song, Joo Han, Lee, Eun Hye, Lee, Hyejon, Sim, Bora, Kim, Song Yee, Chung, Kyung Soo, Kim, Eun Young, Jung, Ji Ye, Park, Moo Suk, Kim, Young Sam, Chang, Joon, Kang, Young Ae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773481/
https://www.ncbi.nlm.nih.gov/pubmed/29348638
http://dx.doi.org/10.1038/s41598-018-19523-7
_version_ 1783293566572822528
author Leem, Ah Young
Song, Joo Han
Lee, Eun Hye
Lee, Hyejon
Sim, Bora
Kim, Song Yee
Chung, Kyung Soo
Kim, Eun Young
Jung, Ji Ye
Park, Moo Suk
Kim, Young Sam
Chang, Joon
Kang, Young Ae
author_facet Leem, Ah Young
Song, Joo Han
Lee, Eun Hye
Lee, Hyejon
Sim, Bora
Kim, Song Yee
Chung, Kyung Soo
Kim, Eun Young
Jung, Ji Ye
Park, Moo Suk
Kim, Young Sam
Chang, Joon
Kang, Young Ae
author_sort Leem, Ah Young
collection PubMed
description Multiple cytokines and inflammatory markers control TB infection. We aimed to investigate the changes in multiple cytokines and inflammatory markers in active TB patients following anti-TB drug therapy. Twenty-nine patients with active TB were recruited prospectively between December 2010 and July 2017. Blood samples were collected before (T(0)), after 2 months (T(2)), and at the end of anti-TB treatment (T(end)). We measured the levels of Interferon (IFN)-γ, interleukin (IL)-2, IL-12, IL-10, IL-13 and tumor necrosis factor (TNF)-α in supernatants collected from the QuantiFERON-TB Gold In-Tube assay (QFT-GIT), as well as the WBC, neutrophil, platelet count and neutrophil to lymphocyte ratio (NLR) in whole blood. Compared with baseline levels, WBC, neutrophil, and platelet counts were significantly lower following treatment. In addition, the NLR after treatment significantly decreased compared with baseline, whereas the IL-2/IFN-γ ratio increased after treatment. In conclusion, the levels of IL-2/IFN-γ ratios in the supernatant and the NLR might be useful biomarkers to evaluate the effectiveness of drug therapy in active TB patients.
format Online
Article
Text
id pubmed-5773481
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-57734812018-01-26 Changes in cytokine responses to TB antigens ESAT-6, CFP-10 and TB 7.7 and inflammatory markers in peripheral blood during therapy Leem, Ah Young Song, Joo Han Lee, Eun Hye Lee, Hyejon Sim, Bora Kim, Song Yee Chung, Kyung Soo Kim, Eun Young Jung, Ji Ye Park, Moo Suk Kim, Young Sam Chang, Joon Kang, Young Ae Sci Rep Article Multiple cytokines and inflammatory markers control TB infection. We aimed to investigate the changes in multiple cytokines and inflammatory markers in active TB patients following anti-TB drug therapy. Twenty-nine patients with active TB were recruited prospectively between December 2010 and July 2017. Blood samples were collected before (T(0)), after 2 months (T(2)), and at the end of anti-TB treatment (T(end)). We measured the levels of Interferon (IFN)-γ, interleukin (IL)-2, IL-12, IL-10, IL-13 and tumor necrosis factor (TNF)-α in supernatants collected from the QuantiFERON-TB Gold In-Tube assay (QFT-GIT), as well as the WBC, neutrophil, platelet count and neutrophil to lymphocyte ratio (NLR) in whole blood. Compared with baseline levels, WBC, neutrophil, and platelet counts were significantly lower following treatment. In addition, the NLR after treatment significantly decreased compared with baseline, whereas the IL-2/IFN-γ ratio increased after treatment. In conclusion, the levels of IL-2/IFN-γ ratios in the supernatant and the NLR might be useful biomarkers to evaluate the effectiveness of drug therapy in active TB patients. Nature Publishing Group UK 2018-01-18 /pmc/articles/PMC5773481/ /pubmed/29348638 http://dx.doi.org/10.1038/s41598-018-19523-7 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Leem, Ah Young
Song, Joo Han
Lee, Eun Hye
Lee, Hyejon
Sim, Bora
Kim, Song Yee
Chung, Kyung Soo
Kim, Eun Young
Jung, Ji Ye
Park, Moo Suk
Kim, Young Sam
Chang, Joon
Kang, Young Ae
Changes in cytokine responses to TB antigens ESAT-6, CFP-10 and TB 7.7 and inflammatory markers in peripheral blood during therapy
title Changes in cytokine responses to TB antigens ESAT-6, CFP-10 and TB 7.7 and inflammatory markers in peripheral blood during therapy
title_full Changes in cytokine responses to TB antigens ESAT-6, CFP-10 and TB 7.7 and inflammatory markers in peripheral blood during therapy
title_fullStr Changes in cytokine responses to TB antigens ESAT-6, CFP-10 and TB 7.7 and inflammatory markers in peripheral blood during therapy
title_full_unstemmed Changes in cytokine responses to TB antigens ESAT-6, CFP-10 and TB 7.7 and inflammatory markers in peripheral blood during therapy
title_short Changes in cytokine responses to TB antigens ESAT-6, CFP-10 and TB 7.7 and inflammatory markers in peripheral blood during therapy
title_sort changes in cytokine responses to tb antigens esat-6, cfp-10 and tb 7.7 and inflammatory markers in peripheral blood during therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773481/
https://www.ncbi.nlm.nih.gov/pubmed/29348638
http://dx.doi.org/10.1038/s41598-018-19523-7
work_keys_str_mv AT leemahyoung changesincytokineresponsestotbantigensesat6cfp10andtb77andinflammatorymarkersinperipheralbloodduringtherapy
AT songjoohan changesincytokineresponsestotbantigensesat6cfp10andtb77andinflammatorymarkersinperipheralbloodduringtherapy
AT leeeunhye changesincytokineresponsestotbantigensesat6cfp10andtb77andinflammatorymarkersinperipheralbloodduringtherapy
AT leehyejon changesincytokineresponsestotbantigensesat6cfp10andtb77andinflammatorymarkersinperipheralbloodduringtherapy
AT simbora changesincytokineresponsestotbantigensesat6cfp10andtb77andinflammatorymarkersinperipheralbloodduringtherapy
AT kimsongyee changesincytokineresponsestotbantigensesat6cfp10andtb77andinflammatorymarkersinperipheralbloodduringtherapy
AT chungkyungsoo changesincytokineresponsestotbantigensesat6cfp10andtb77andinflammatorymarkersinperipheralbloodduringtherapy
AT kimeunyoung changesincytokineresponsestotbantigensesat6cfp10andtb77andinflammatorymarkersinperipheralbloodduringtherapy
AT jungjiye changesincytokineresponsestotbantigensesat6cfp10andtb77andinflammatorymarkersinperipheralbloodduringtherapy
AT parkmoosuk changesincytokineresponsestotbantigensesat6cfp10andtb77andinflammatorymarkersinperipheralbloodduringtherapy
AT kimyoungsam changesincytokineresponsestotbantigensesat6cfp10andtb77andinflammatorymarkersinperipheralbloodduringtherapy
AT changjoon changesincytokineresponsestotbantigensesat6cfp10andtb77andinflammatorymarkersinperipheralbloodduringtherapy
AT kangyoungae changesincytokineresponsestotbantigensesat6cfp10andtb77andinflammatorymarkersinperipheralbloodduringtherapy